Navigating the MRD Controversy in CLL

Exploring the challenges and potential benefits of minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL), including discussions on MRD-guided trials, time-limited therapy, targeted agent doublets, and the debate between triplet and doublet therapies.